Insulet Corporation with ticker code (PODD) now have 19 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $270.00 and $185.00 suggesting an average Analsyt target price of $232.90. Given that the stocks previous close was at $165.90 and the analysts are correct then we can expect a percentage increase in value of 40.4%. It’s also worth noting that there is a 50 day moving average of $170.31 while the 200 day moving average is $182.36. The market cap for the company is 11.28B. The stock price for the company is currently is currently $161.02 USD
The potential market cap would be $15,832,372,886 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 48.35, revenue per share of $25.50 and a 6.74% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
